PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Launch
Sanofi's Aubagio to Square Off Against MS Injectables
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28.
Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – [...]
Posted in FDA, Regulatory, Safety, Strategy, pricing Also tagged drug approvals, Genzyme, MS, Sanofi 2 Comments
Using Social Networks to Increase Sales
Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.
Posted in Advertising, Marketing, Sales, Strategy, Technology, leadership, social media Also tagged Activate Networks, analytics, conference, Genentech, marketing research, physicians, Sales, sales force, sales rep, social networks Leave a comment
Lilly's Decentralized Global Launch Strategy
Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
First Orphan Launch a Challenge for AstraZeneca
Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names.
Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, isn’t [...]
Posted in FDA, Marketing, Safety, Strategy, patient education Also tagged AstraZeneca, Cancer, Orphan Drugs, Sales, Ultra Orphan Leave a comment
Diabetes Drug Launch 2012: Tip-tops and Promo-flops